Diagnostics/radiopharma sales decline at Schering AG:
This article was originally published in Clinica
Executive Summary
Declines in sales of X-ray contrast media and radiopharmaceuticals led to a 3% fall in net sales at Schering AG's diagnostics and radiopharmaceuticals business in 2002. Total divisional revenues of E1,406m ($1,525m) included E327m from MRI contrast agents (+2%) and E264m from contrast agent application technologies (+9%), but X-ray contrast media fell by 9% to E654m and there was a 4% decrease in radiopharmaceutical sales to E146m. The company was hit by negative price pressures and exchange rate effects.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.